share_log

Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $16

Benzinga Real-time News ·  Aug 9, 2022 08:54

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and raises the price target from $14 to $16.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment